The use of the internet has evolved in quantitative structure–activity relationship (QSAR) over the past decade with the development of web based activities like the availability of numerous public domain software tools for descriptor calculation and chemometric toolboxes. The importance of chemometrics in QSAR has accelerated in recent years for processing the enormous amount of information in form of predictive mathematical models for large datasets of molecules. With the availability of huge numbers of physicochemical and structural parameters, variable selection became crucial in deriving interpretable and predictive QSAR models. Among several approaches to address this problem, the principle component regression (PCR) and partial least squares (PLS) analyses provide highly predictive QSAR models but being more abstract, they are difficult to understand and interpret. Genetic algorithm (GA) is a stochastic method well suited to the problem of variable selection and to solve optimization problems. Consequently the hybrid approach (GA-MLR) combining GA with multiple linear regression (MLR) may be useful in derivation of highly predictive and interpretable QSAR models. In view of the above, a comparative study of stepwise-MLR, PLS and GA-MLR in deriving QSAR models for datasets of α1-adrenoreceptor antagonists and β3-adrenoreceptor agonists has been carried out using the public domain software Dragon for computing descriptors and free Matlab codes for data modeling.
1 February 2015 in Bioorganic & Medicinal Chemistry
Background: The cancer is still a major cause of death worldwide. Among different targets to design anticancer agents, caspase-3 is an important target as its cleavage and activation lead to apoptosis and finally, cancer cell death. Apart from some naturally occurring molecules, many small molecules have been reported as caspase-3 activators. Objectives: In view of the above, the objective has been to review the published work on small molecules reported as caspase-3 activators and their anticancer activity to get some novel lead molecules for designing novel molecules of improved cancer therapeutic. Methods: Literature search has been carried out using different search engines like google, Elsevier, Science direct, RSC, etc. for the publications of small molecules as caspase-3 activators inducing apoptosis in cancer cells. Results: In this review, the small molecules showing caspase-3 cleavage and activation have been discussed under different broad chemical classes so as to provide some insight into the structural features responsible for caspase-3 activation leading to anticancer activity. The review also encompasses the established drugs, novel organometallics showing caspase-3 activation and anticancer activity. Conclusion: A large number of small molecules including some established drugs and organometallics have shown cleavage and activation of caspase-3 leading to apoptosis and anticancer activity. Many reported potent molecules of different chemical classes may be useful as lead molecules for optimization of anticancer activity as well as they may provide an insight of structural features which may be useful in designing novel caspase-3 activators as anticancer agents for drug development.
15 May 2009 in Journal of Chemical Information and Modeling
A pharmacophore model has been developed using diverse classes of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitors useful in the treatment of human tumours. Among the top 10 generated hypotheses, the second hypothesis, with one hydrogen bond acceptor, one ring aromatic and three hydrophobic features, was found to be the best on the basis of Cat Scramble validation as well as test set prediction (rtraining = 0.89, rtest = 0.82). The model also maps well to the external test set molecules as well as clinically active molecules and corroborates the docking studies. Finally, 10 hits were identified as potential leads after virtual screening of ZINC database for EGFR TK inhibition. The study may facilitate the designing and discovery of novel EGFR TK inhibitors.